You are here
Global Diabetic Neuropathy Drugs Market to 2023 - Key Vendors are Daiichi Sankyo Co, Eli Lilly and Co, Johnson & Johnson Services, Novartis, & Pfizer
DUBLIN, May 2, 2019 /PRNewswire/ -- The "Global Diabetic Neuropathy Drugs Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
The diabetic neuropathy drugs market will register a CAGR of about 6% by 2023.
The rising awareness about diabetic neuropathy is one of the prominent factors likely to contribute to the diabetic neuropathy drugs market growth in the forthcoming years. Several awareness programs are being launched among the consumers with an aim to educate and train diabetes educators in the emerging and advanced economies. Different campaigns are encouraging people to take an online test for knowing about the risk factors associated with prediabetes, in turn, driving the diabetic neuropathy drugs market growth during the forecast period.
New drug approvals and strong drug pipeline
One of the growth drivers of the global diabetic neuropathy drugs market is new drug approvals and strong drug pipeline. With the rising prevalence of diabetic neuropathy, several market players are focusing on the development of disease-modifying drugs to treat the disease.
Side-effects of major drugs
One of the challenges in the growth of the global diabetic neuropathy drugs market is the side-effects of major drugs. Side-effects associated with approved drugs such as pregabalin (LYRICA) and gabapentin (NEURONTIN) can lead to low patient compliance, thereby hindering the growth of the market.
The market appears to be moderately fragmented with the presence of several market players. Vendors in the market are focusing on the development of novel biologics to treat diabetic neuropathy. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.
Key Topics Covered:
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 06: CUSTOMER LANDSCAPE
PART 07: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2018-2023
- Europe - Market size and forecast 2018-2023
- Asia - Market size and forecast 2018-2023
- ROW - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 08: MARKET SEGMENTATION BY MECHANISM OF ACTION
- Market segmentation by mechanism of action
- Comparison by mechanism of action
- Calcium channel alpha-2-delta ligand - Market size and forecast 2018-2023
- SNRIs and TCAs - Market size and forecast 2018-2023
- Others - Market size and forecast 2018-2023
- Market opportunity by mechanism of action
PART 09: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 10: MARKET TRENDS
PART 11: VENDOR LANDSCAPE
- Landscape disruption
- Competitive scenario
PART 12: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Daiichi Sankyo Company, Limited
- Eli Lilly and Company
- Johnson & Johnson Services, Inc.
- Novartis AG
- Pfizer Inc.
PART 13: APPENDIX
For more information about this report visit https://www.researchandmarkets.com/r/drx6lk
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:http://www.prnewswire.com/news-releases/global-diabetic-neuropathy-drugs-market-to-2023---key-vendors-are-daiichi-sankyo-co-eli-lilly-and-co-johnson--johnson-services-novartis--pfizer-300842014.html
SOURCE Research and Markets